S. Mark Tompkins, PhD

Research Interest

Dr. Tompkins’ research focuses on understanding the emergence, pathogenesis, prevention, and treatment of influenza viruses. These studies include surveillance for influenza virus in animal populations, susceptibility to influenza infection, and influenza virus evolution. Areas of research include dissecting virus-host interactions at the cellular and host level and exploiting these interactions to collaboratively develop novel vaccines, antiviral drugs, and treatments for human and animal use. Dr. Tompkins’ team has established several animal models of human, avian, and swine influenza virus infection, including emerging viruses requiring BSL3 biocontainment. His laboratory utilizes mouse, ferret and swine models of infection to understand the host response to infection and vaccination, as well as assessing vaccine and therapeutic efficacy.

Lab Focus

Emergence of influenza A viruses

• Assessment of pathogenesis of emerging viruses in multiple animal models
• Understanding fitness determinants of influenzas viruses enabling crossing species barriers
• Assessment of efficacy of existing vaccines and antiviral treatments against emerging influenza viruses

Interactions of the host and virus

• Identification of virulence determinants in influenza viruses
• Host determinants of susceptibility to infection and disease
• Cellular and humoral immune responses to influenza virus infection
• Contribution of the microbiome to influenza virus infection and disease
• Bacterial co-infections in influenza virus infection and disease

Human seasonal, swine, and avian influenza A virus challenge models for vaccine, antiviral drug, and therapeutic efficacy

• Mouse models of infection, including extensive immune response analysis, efficacy in prevention of clinical disease, and pathologic analysis
• Ferret model of infection, including limited immune response analysis, efficacy in prevention of clinical disease and transmission, and pathologic analysis
• Domestic swine model of infection, including immune response analysis, in prevention of clinical disease and transmission, and pathologic analysis

Novel co-infection models to assess for vaccine, antiviral drug, and therapeutic efficacy

• Mouse model of infection with respiratory syncytial virus (RSV)
• Mouse model of co-infection of RSV and influenza virus
• Ferret model of co-infection of Streptococcus pneumoniae and influenza virus (preliminary)
• Ferret model of infection with Bordetella bronchiseptica (preliminary)

Recent Publications

Albrecht RA, Liu WC, Sant AJ, Tompkins SM, Pekosz A, Meliopoulos V, Cherry S, Thomas PG, Schultz-Cherry S. (2018) Moving Forward: Recent Developments for the Ferret Biomedical Research Model. MBio. 9(4). pii: e01113-18. doi: 10.1128/mBio.01113-18. PMID: 30018107

Nachbagauer R, Shore D, Yang H, Johnson SK, Gabbard JD, Tompkins SM, Wrammert J, Wilson PC, Stevens J, Ahmed R, Krammer F, and AH Ellebedy (2018) Broadly-reactive human monoclonal antibodies elicited following pandemic H1N1 influenza virus exposure protect mice from highly pathogenic H5N1 challenge. J Virol. 2018 Jun 13. pii: JVI.00949-18. doi: 10.1128/JVI.00949-18. PMID: 29899095

Yoon JJ, Toots M, Lee S, Lee ME, Ludeke B, Luczo JM, Ganti K, Cox RM, Sticher ZM, Edpuganti V, Mitchell DG, Lockwood MA, Kolykhalov AA, Greninger AL, Moore ML, Painter GR, Lowen AC, Tompkins SM, Fearns R, Natchus MG, and RK Plemper. (2018) Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses. Antimicrob Agents Chemother. 2018 Jun 11. pii: AAC.00766-18. doi: 10.1128/AAC.00766-18. PMID: 29891600

Wei H, Chen Z, Elson A, Li Z, Abraham M, Phan S, Kristhnamurthy S, McCray Jr PB, Andrews S, Stice S, Sakamoto K, Jones C, Tompkins SM, and B He (2017) Developing a platform system for gene delivery: amplifying virus-like particles (AVLP) as an influenza vaccine. npj Vaccines 2017; 2:32. doi:10.1038/s41541-017-0031-7. PMID: 29263887

SJ Samet and SM Tompkins. (2017) Influenza Pathogenesis in Genetically Defined Resistant and Susceptible Murine Strains. Yale J Biol Med. 2017 Sep 25;90(3):471-479. eCollection 2017. PMID: 28955185

Mooney, AJ, Gabbard, JD, Li, Z, Dlugolenski, DA, Johnson, SK, Tripp, RA, He, B, and SM Tompkins. (2017) Vaccination with recombinant PIV5 expressing influenza neuraminidase provides protection against homologous and heterologous influenza virus infection. J Virol. 2017 Sep 20. pii: JVI.01579-17. doi: 10.1128/JVI.01579-17. PMID: 28931689

Zanin M, Kocer Z, Poulson P, Gabbard G, Howerth E, Jones C, Friedman K, Seiler J, Danner A, Kercher L, McBride R, Paulson J, Wentworth D, Krauss S, Tompkins SM, Stallknecht D, and R Webster (2017) The Potential for Low Pathogenic Avian H7 Influenza A Viruses to Replicate and Cause Disease in a Mammalian Model. J Virol. 2017 Jan 18;91(3). pii: e01934-16. doi: 10.1128/JVI.01934-16. PMID: 27852855. Cover Article. Spot Light Article

Jara AL, Hanson JM, Gabbard JD, Johnson SK, Register ET, He B, and SM Tompkins (2016) Comparison of Microchip Transponder and Noncontact Infrared Thermometry with Rectal Thermometry in Domestic Swine (Sus scrofa domestica). J Am Assoc Lab Anim Sci. 2016;55(5):588-93. PMID: 27657715

Wang L, Chang TZ, He Y, Kim JR, Wang S, Mohan T, Berman Z, Tompkins SM, Tripp RA, Compans RW, Champion JA, Wang BZ. (2116) Coated protein nanoclusters from influenza H7N9 HA are highly immunogenic and induce robust protective immunity. Nanomedicine. 2016 Sep 10. pii: S1549-9634(16)30151-4. PMID: 27622321

Poulson RL, Tompkins SM, Berghaus RD, Brown JD, Stallknecht DE. (2016) Environmental Stability of Swine and Human Pandemic Influenza Viruses in Water Under Variable Conditions of Temperature, Salinity, and pH. Appl Environ Microbiol. 82(13):3721-3726. doi: 10.1128/AEM.00133-16.PMID: 27084011

Deffrasnes C, Marsh GA, Foo CH, Rootes CL, Gould CM, Grusovin J, Monaghan P, Tompkins SM, Adams TE, Lowenthal JW, Simpson KJ, Stewart CR, Bean AG, and LF Wang. (2016) Genome-wide siRNA Screening at Biosafety Level 4 Reveals a Crucial Role for Fibrillarin in Henipahvirus infection. PLoS Pathog. 2016 Mar 24;12(3):e1005478. PMID: 27010548 Featured Article

van der Sanden SM, Wu W, Dybdahl-Sissoko N, Weldon WC, Brooks P, O'Donnell J, Jones LP, Brown C, Tompkins SM, Oberste MS, Karpilow J, Tripp RA. (2015) Engineering Enhanced Vaccine Cell Lines to Eradicate Vaccine-Preventable Diseases: The Polio Endgame. J Virol. 2015 Nov 18. pii: JVI.01464-15. PMID: 26581994

Choi J, Martin SJ, Tripp RA, Tompkins SM, Dluhy RA. (2115) Detection of Neuraminidase Stalk Motifs Associated with Enhanced N1 Subtype Influenza A Virulence via Raman Spectroscopy. Analyst. 140(22):7748-60. doi: 10.1039/c5an00977d. PMID: 26460183

Ridenour C, Williams SM, Jones L, Tompkins SM, Tripp RA, Mundt E. Serial passage in ducks of a low-pathogenic avian influenza virus isolated from a chicken reveals a high mutation rate in the hemagglutinin that is likely due to selection in the host. Arch Virol. 2015. doi: 10.1007/s00705-015-2504-1. PMID: 26179620

Li Z, Gabbard JD, Johnson S, Dlugolenski D, Phan S, Tompkins SM, He B. Efficacy of a parainfluenza virus 5 (PIV5)-based H7N9 vaccine in mice and guinea pigs: antibody titer towards HA was not a good indicator for protection. PLoS One. 2015;10(3):e0120355. doi: 10.1371/journal.pone.0120355. PMID: 25803697

Fox JM, Crabtree JM, Sage LK, Tompkins SM, Tripp RA. Interferon Lambda Upregulates IDO1 Expression in Respiratory Epithelial Cells After Influenza Virus Infection. J Interferon Cytokine Res. 2015;35(7):554-62. doi: 10.1089/jir.2014.0052. PMID: 25756191

McMaster SR, Gabbard JD, Koutsonanos DG, Compans RW, Tripp RA, Tompkins SM, Kohlmeier JE. Memory T cells generated by prior exposure to influenza cross react with the novel H7N9 influenza virus and confer protective heterosubtypic immunity. PLoS One. 2015;10(2):e0115725. doi: 10.1371/journal.pone.0115725. PMID: 25671696

Temple BL, Finger JW, Jr., Jones CA, Gabbard JD, Jelesijevic T, Uhl EW, Hogan RJ, Glenn TC, Tompkins SM. In ovo and in vitro susceptibility of American alligators (Alligator mississippiensis) to avian influenza virus infection. J Wildl Dis. 2015;51(1):187-98. doi: 10.7589/2013-12-321. PMID: 25380354

Lebarbenchon C, Pedersen JC, Sreevatsan S, Ramey AM, Dugan VG, Halpin RA, Ferro PJ, Lupiani B, Enomoto S, Poulson RL, Smeltzer M, Cardona CJ, Tompkins SM, Wentworth DE, Stallknecht DE, Brown JD. H7N9 influenza A virus in turkeys in Minnesota. J Gen Virol. 2015;96(Pt 2):269-76. doi: 10.1099/vir.0.067504-0. PMID: 25351723

Perwitasari O, Johnson S, Yan X, Howerth E, Shacham S, Landesman Y, Baloglu E, McCauley D, Tamir S, Tompkins SM, Tripp RA. Verdinexor, a novel selective inhibitor of nuclear export, reduces influenza a virus replication in vitro and in vivo. J Virol. 2014;88(17):10228-43. doi: 10.1128/JVI.01774-14. PMID: 24965445

Negri P, Choi JY, Jones C, Tompkins SM, Tripp RA, Dluhy RA. Identification of virulence determinants in influenza viruses. Anal Chem. 2014;86(14):6911-7. doi: 10.1021/ac500659f. PMID: 24937567

McCutcheon KM, Gray J, Chen NY, Liu K, Park M, Ellsworth S, Tripp RA, Tompkins SM, Johnson SK, Samet S, Pereira L, Kauvar LM. Multiplexed screening of natural humoral immunity identifies antibodies at fine specificity for complex and dynamic viral targets. MAbs. 2014;6(2):460-73. doi: 10.4161/mabs.27760. PMID: 24492306

Perwitasari O, Yan X, Johnson S, White C, Brooks P, Tompkins SM, Tripp RA. Targeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy. Antimicrob Agents Chemother. 2013;57(1):475-83. doi: 10.1128/AAC.01532-12. PMID: 23129053

Gabbard JD, Dlugolenski D, Van Riel D, Marshall N, Galloway SE, Howerth EW, Campbell PJ, Jones C, Johnson S, Byrd-Leotis L, Steinhauer DA, Kuiken T, Tompkins SM, Tripp R, Lowen AC, Steel J. Novel H7N9 influenza virus shows low infectious dose, high growth rate, and efficient contact transmission in the guinea pig model. J Virol. 2014;88(3):1502-12. doi: 10.1128/JVI.02959-13. PMID: 24227867 Spot Light Article

PubMed

Complete List of Published Work in PUBMED